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Abstract
Drugs inhibiting the influenza A virus (IAV) neuraminidase (NA) are the cornerstone of anti-IAV chemotherapy and
prophylaxis in man. Drug-resistant mutations in NA arise frequently in human isolates, limiting the therapeutic application
of NA inhibitors. Here, we show that antibody-driven antigenic variation in one domain of the H1 hemagglutinin Sa site
leads to compensatory mutations in NA, resulting in NA antigenic variation and acquisition of drug resistance. These
findings indicate that influenza A virus resistance to NA inhibitors can potentially arise from antibody driven HA escape,
confounding analysis of influenza NA evolution in nature.
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Introduction
The hemagglutinin (HA) and neuraminidase (NA) glycopro-
teins of influenza A virus (IAV) regulate viral attachment, entry,
and release from cells. By binding terminal sialic acids, HA
attaches virus to the cell surface to initiate the infectious cycle.
By cleaving terminal sialic acids, NA releases virions from cells
and substances that can interfere with viral attachment.
Maximal viral fitness requires compatibility between the HA
and NA, though the underlying mechanisms are incompletely
understood.
Oseltamivir and zanamivir are NA active site inhibitors
approved for use in humans [1]. Mutants resistant to these drugs
are readily selected in cell culture [2,3,4,5], suggesting that
widespread use of these drugs has promoted the emergence of
drug-resistant IAV strains in humans. This conclusion is supported
by the temporal correlation between drug use and emergence of
resistant mutants, and more directly by the isolation of NA
mutants from chronically infected individuals treated with NA
inhibitors [6]. By contrast, epidemiological studies failed to
correlate drug use and resistance [7,8,9], suggesting the partici-
pation of additional factors in selection.
NA-inhibitor resistant mutants are often compensated by
changes in HA to restore viral fitness [3,10,11,12]. Many of these
changes alter HA affinity for sialic acids. We recently reported that
many of the amino substitutions in HA selected for escape from
neutralizing monoclonal antibodies (mAbs) modulate HA avidity
for host cells [13]. This prompts the question, do some of these
substitutions provoke compensatory NA mutations to maximize
viral fitness?
Results
We addressed this question by sequencing both HA and NA
genes of 40 previously described anti-HA mAb escape mutants
(mutants are named based on their selecting mAb). As reported
[14], each variant possessed the previously reported mutation
leading to an amino acid substitution in their corresponding
HA epitopes (Table 1). Three of the 40 viruses, CV1, KV2,
JV9, possessed a non-synonymous mutation in their NA genes
at positions 274, 253, and 118, while the other 37 viruses had
the wt sequence. Remarkably, for viruses with NA mutations,
the HA substitutions form a clear pattern, since they are all
located at the edge of the Sa antigenic site at the HA trimer
interface, occupying positions K163T, K165E, and S167F
(Fig. 1a). Each substitution in NA is located at a different NA
residue (Fig. 1b).
The correlation between alterations in this Sa subsite was
confirmed by selecting escape mutants with a mixture of Sa-site
specific mAbs. Once again, we obtained the K163T substitution,
which was accompanied by a T191I NA substitution. Three
other escape mutants characterized from the same selection
experiment, N129K, N129D, and P162Q had no changes in NA
gene sequence. It is nearly impossible statistically for the
sequence change in NA that accompanies the K163T mutation
to arise from chance in two separate selection experiments
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that chance is responsible for NA sequence changes in the three
adjacent Sa residues. Rather, we conclude that amino acid
alterations in this region must reduce viral fitness in a manner
that selects for compensatory non-synonymous mutations in the
NA gene.
What are the effects of these NA substitutions on viral NA
activity? CV1, KV2, and JV9 demonstrated reduced NA activity
per virion relative to wt virus, as measured by hydrolysis of the NA
substrate 29-4-Methylumbelliferyl-alpha-D-N-acetyneuraminic ac-
id (Fig. 1c). NA activity was reduced independently of HA
physical proximity, as indicated by treating virus with Triton-X
100, a mild detergent that dissociates viral membranes, releasing
the glycoproteins from virions. To address the extent to which the
mutations reduced NA content per virion vs. intrinsically reduced
NA activity, we quantified viral proteins present in purified virions
by ELISA (Fig. 1d), western blots (Fig. 1e), and total protein stain
(Fig. 1f), normalizing viral quantities by the amount of total
protein present in a solution based assay. Reassuringly, the mutant
viruses had indistinguishable levels of HA, NP, and M1.
Surprisingly, two of the viruses (CV1 and KV2) exhibited reduced
amounts of NA relative to other viral proteins. Thus, compensa-
tory NA mutations diminish NA activity by intrinsic effects on
enzyme activity and in two cases, by reducing NA incorporation
per virion. We did not fully characterize the T191I NA mutation
that emerged in our 2
nd selection experiments, but based on
observation that this amino acid is located far from the NA active
site we expect that this mutation likely affects NA activity by
reducing NA incorporation into virions, rather than directly
altering enzymatic activity.
NA mutations in CV1 (H274N), and JV9 (V118I) are in close
proximity to the active site, while the mutation in KV2 (K253R) is
a bit more distant. Substitutions at 253 are known to modulate NA
antigenicity [15] and substitutions at residue 274 are known to
modulate resistance to oseltamivir [16,17,18]. Could the anti-HA
mAb escape mutants exhibit altered NA drug sensitivity or
antigenicity? We found that CV1 is dramatically resistant to
zanamivir and more sensitive to oseltamivir (Fig. 2a–b). During
the 2008–09 influenza season, the majority of H1N1 IAVs
possessed the H274Y NA mutation which promoted oseltamivir
resistance. The difference in drug sensitivity between CV1 and the
2008–09 seasonal variants (ie: more sensitive to oseltamivir versus
more resistance to oseltamivir) is likely due to the specific amino
acid substitution (H274N versus H274Y). Next, we examined NA
antigenicity by measuring the binding affinity of anti-NA mAbs to
the mutant viruses. Each of the mAbs used is specific for native NA
and blocks NA activity using fetuin as a substrate. The mutation in
CV1 resulted in a major NA antigenic change, as determined by
reduced binding of 3 anti-NA mAbs (Fig. 2c). Taken together,
these data demonstrate that IAVs can become resistant to NA
inhibitors and exhibit altered NA antigenicity in response to Ab
pressure on HA, in this particular circumstance, one region of the
Sa site in the PR8 HA.
Discussion
Recent findings indicate that certain mutations in NA allow the
molecule to become promiscuous for additional mutations that
confer drug resistance [19]. Our findings have similar implications
for understanding NA evolution in man: anti-HA Ab driven
escape can possibly select for compensatory changes in NA that
alter drug resistance. This phenomenon provides a potential
explanation for the poor correlation between NA inhibitor use and
emergence of drug-resistant strains. Another important implica-
tion from our studies is that a significant amount of NA antigenic
drift may be a byproduct of HA antigenic drift.
We are uncertain of the underlying mechanism that promotes
selection of mutated NA in our experimental system. There are no
simple correlations between HA receptor binding avidity and the
emergence of compensatory NA mutations. For example, the HA
mutation, K165E, increases receptor binding avidity whereas the
mutations, K163T or S167F, do not apparently alter receptor
Table 1. Amino acid substitutions in HA mAb-selected
variants.
Vrus HA NA
BV1 E156G
BV2 Q196R
BV6 G159D
BV11 Q192L
BV12 N193S
BV13 N193K
CV1 K165E H274N
CV5 P128S
CV8 N166K
CV9 P162L
CV10 L164Q
DV4 S140P
DV5 R224I
DV6 G143R
EV1 E156K
EV2 Q192R
EV8 E198G
HV1 G173E
JV3 S167Y
JV9 S167F V118I
KV2 K163T K253R
KV3 N129K
LV1 R78G
MV4 L75P
MV5 S79P
MV9 V77E
NV7 S145G
NV8 S145N
PV8 S160L
PV12 N129Y
PV20 E158V
RV2 E119G
RV3 E119K
RV7 L74P
SV5 I93T
SV7 G240R
WV7 I244T
WV10 V169A
WV11 G173R
WV15 G240E
doi:10.1371/journal.pone.0015190.t001
HA-NA Compensation
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measure overall avidity to many different glycans expressed on red
blood cells, and an intriguing possibility is that NA mutations arise
to restore balance to the binding/cleavage to specific glycans.
Further elucidation of mechanisms that promote NA compensa-
tory mutations may facilitate early identification of drug resistant
IAV strains in the human population.
Materials and Methods
Sequencing
RNA was extracted from virus stocks using a QiAmp viral RNA
mini kit. For each RNA extraction, we started with 140 ul of virus
in allantoic fluid. cDNA was made and HA and NA genes were
amplified by PCR. Sequencing was performed on an AppliedBio-
system DNA analyzer.
Enzyme Activity
NA activity was determined as previously described [20] with
slight modifications. For these assays, we used purified viruses.
Virus amounts were adjusted based on NA levels as determined
by ELISA (for each assay, this corresponded to approximately
50–100 HAUs of virus/sample). Viruses were diluted in assay
buffer (33 mM MES (pH 6.5), 4 mM CaCl2) and 200 uM of 29-
4-Methylumbelliferyl-alpha-D-N-acetyneuraminic acid was add-
ed. Samples were placed in black flat bottom plates at 37uC and
O.D. (Ex=365 nm; Em=450 nm) readings were recorded every
minute for 30 minutes. Data are expressed as the rate of
enzymatic activity (relative vmax). For some experiments, viruses
were pre-incubated with 1% Triton-X to disrupt viral mem-
branes. For other experiments, viruses were pre-incubated for
1 hour at 37uC with increasing amounts of oseltamivir or
zanamivir.
Figure 1. Compensatory NA mutations decrease NA activity. Three-dimensional view of HA trimer (a) and NA tetramer (b). Mutations found in
individual viruses are in different colors (yellow=CV1, orange=KV2, green=JV9). Sialic acid (a) and the NA active site (b) are shown in red. (c) NA
activities of viruses +/2 Triton-X were determined using a colorimetric assay. The amount of glycoproteins incorporated in purified virions was
determined by ELISA (d), western blots (e), and total protein blots (f). *, p,0.05 compared to PR8.
doi:10.1371/journal.pone.0015190.g001
HA-NA Compensation
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For glycoprotein quantification studies, plates were coated with
150 ng/mL of purified virions diluted in PBS (as determined using
the BioRad DC protein assay) overnight at 4uC and then blocked
for 1 hour at room temperature with PBS-FBS. A saturating
amount of either a purified HA mAb (CM1) (diluted 1:100) or
polyclonal rabbit anti-NA Ab mixture (diluted 1:200) was then
added and allowed to incubate for 2 hours at room temperature.
Anti-mouse or anti-rabbit HRP (diluted 1:4000) was then added
and allowed to incubate for 1 hour at room temperature. TMB
substrate was added and the reaction was stopped with HCL and
O.D.s were measured at 450 nm. For mAb escape experiments,
plates were coated overnight at 4uC with viruses that were
normalized based on NA amount (this corresponds to ,50–
100 HAU/well). The ELISAs were carried out as described above
except decreasing amounts of mAb or polyclonal Abs were used.
Based on these Ab titrations, Kd were calculated and relative
binding affinities based on these Kd were graphed. For this set of
experiments, data were graphed using the previously described
matrix2png software [21]. Between all ELISA steps, plates were
washed with PBS-tween.
Immunoblots
Purified virions (3 ug as determined using BioRad DC protein
assay) were mixed with SDS-PAGE buffer and run on a 12% SDS-
PAGE gel and the gels were blotted on nitrocellulose. These
membranes were then incubated with an anti-HA mAb (CM1)
(hybridoma supernatant diluted 1:1) and rabbit polyclonal anti-NA
Abs (diluted 1:1000) and then with infrared dye coupled secondary
Abs (Donkey anti-mouse IR Dye 800 and Donkey anti-rabbit IR
Dye 680—each diluted 1:10,000). Blots were analyzed using an
Odyssey imaging system. For other experiments, non-reduced
samples were run on a 12% SDS-PAGE gel and then stained with
Syproruby to visualize total protein content.
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Figure 2. Compensatory mutations alter NA drug sensitivity
and antigenicity. Viruses were pre-incubated with zanamivir (a) or
oseltamivir (b) and NA activity was determined. (c) Relative binding
affinities of 3 control Abs (NA polyclonal Ab, HA mAb, and NP mAb) and
4 anti-NA mAbs were determined using an ELISA assay. Ab titrations
were performed and relative Kd values were transformed into relative
colors using the matrix2png software. Black indicates high binding
affinity and white indicates low binding affinity.
doi:10.1371/journal.pone.0015190.g002
HA-NA Compensation
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